AxoGen, Inc. Announces Publication of Avance® Nerve Graft Clinical Results in The Journal of Hand Surgery

Published, multi-center study reports on outcomes for upper extremity nerves with gaps of 5mm to 50mm in length repaired with Avance® Nerve Graft from AxoGen, Inc.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

AxoGen Logo

“Avance® Nerve Graft offers a viable option for the repair of peripheral nerve defects across a range of gap lengths for both motor and sensory nerves and offers the benefit of eliminating a second surgical incision for nerve harvest.” Gregory Buncke, MD

Alachua, FL (PRWEB) December 03, 2012

AxoGen, Inc. (OTCBB: AXGN), the leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions, announced today that The Journal of Hand Surgery published new clinical results for use of Avance® Nerve Graft for repair of peripheral nerve injuries in the upper extremity.

The Journal of Hand Surgery article included outcomes data for 51 peripheral nerve repairs across 12 leading US surgical institutions (including Level 1 trauma, academic, military and community centers, as well as ambulatory surgery centers). Outcomes were reported for surgical repairs performed on ulnar, median and digital nerves with nerve tissue gaps ranging from 5mm to 50mm in length. Repairs of 5mm – 14mm in length demonstrated 100% meaningful recovery, 15mm – 29mm 74% meaningful recovery and 30mm – 50mm 90% meaningful recovery.

“This study confirms the results that we have observed at our clinical practice for upper extremity nerve repair over the last several years,” noted Gregory Buncke, MD, plastic surgeon, Co-Director of The Buncke Clinic in San Francisco and an author of The Journal of Hand Surgery publication. Dr. Buncke continued, “Avance® Nerve Graft offers a viable option for the repair of peripheral nerve defects across a range of gap lengths for both motor and sensory nerves and offers the benefit of eliminating a second surgical incision for nerve harvest.”

The publication is based on the upper extremity nerve injury subgroup of the RANGER® Study, which the company believes is the largest, multi-center, multi-surgeon study focused on the treatment of peripheral nerve discontinuities. Initiated in 2007, RANGER® tracks outcomes in contemporary clinical practice from the use of Avance® Nerve Graft, the only nerve allograft processed using the Avance® Processing Technique. Previously results from the RANGER® Study, published in the journal Microsurgery in January 2012, demonstrated that across all nerve injury locations and gap lengths, 87% of those repaired using Avance® Nerve Graft reported meaningful recovery.

Avance® Nerve Graft is a processed human nerve allograft intended for bridging peripheral nerve discontinuities and provides surgeons a readily available nerve graft to repair peripheral nerves damaged by traumatic injury or removed during surgical procedures.

A summary of the findings is entitled, “Functional Outcome Following Nerve Repair in the Upper Extremity Using Processed Nerve Allograft” and can be found in the November 2012 edition of The Journal of Hand Surgery or on AxoGen’s website at http://www.AxoGenInc.com.

About AxoGen, Inc.
AxoGen (OTCBB: AXGN) is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. AxoGen’s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves, AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue. For more information, visit our website at http://www.axogeninc.com.

Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “may”, “should”, variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential or financial performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.


Contact